Trial · NCT07851896
Effects of Basic Body Awareness Therapy Added to Aerobic Exercise in Women With Fibromyalgia
NCT07851896, Not applicable, Not yet recruiting, Hacer Önen Tekin
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Effects of Basic Body Awareness Therapy Added to Aerobic Exercise in Women With Fibromyalgia. Trials, record NCT07851896. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07851896
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Basic Body Awareness Therapy Added to Aerobic Exercise in Women With Fibromyalgia
- NCT number
- NCT07851896
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Hacer Önen Tekin
- Conditions
- Fibromyalgia Syndrome
- Interventions
- Basic Body Awareness Therapy, Moderate-Intensity Aerobic Exercise
- First posted
- 2026-10-01
- Last updated
- 2026-10-01
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Interleukin-6 (IL-6) | Baseline (before the first exercise session), after the first exercise session (Day 1), and at the end of 12 weeks. | Changes in serum interleukin-6 (IL-6) concentration will be assessed using standardized laboratory assay methods to evaluate the biological effects of aerobic exercise with or without Basic Body Awareness Therapy in women with fibromyalgia. |
| Primary | Cortisol | Baseline (before the first exercise session), after the first exercise session (Day 1), and at the end of 12 weeks. | Changes in cortisol concentration will be assessed using standardized laboratory assay methods to evaluate the biological effects of aerobic exercise with or without Basic Body Awareness Therapy in women with fibromyalgia. |
| Secondary | Cognitive Function Assessed by Trail Making Test | Baseline (before the first exercise session), after the first exercise session (Day 1), and at the end of 12 weeks. | Cognitive function including attention, processing speed, executive function, and cognitive flexibility will be evaluated using the Trail Making Test (Parts A and B). |
| Secondary | Depression Level Measured by Depression Anxiety Stress Scale-21 (DASS-21) Depression Subscale | Baseline (before the first exercise session), after the first exercise session (Day 1), and at the end of 12 weeks. | Depression levels will be assessed using the Depression subscale of the Depression Anxiety Stress Scale-21 (DASS-21). |
| Secondary | Pain Intensity Measured by Visual Analog Scale (VAS) | Baseline (before the first exercise session), after the first exercise session (Day 1), and at the end of 12 weeks. | Pain intensity will be evaluated using a 10-cm Visual Analog Scale (VAS). |
| Secondary | Pressure Pain Threshold Measured by Pressure Algometer | Baseline (before the first exercise session), after the first exercise session (Day 1), and at the end of 12 weeks. | Pressure pain threshold will be measured using a pressure algometer at standardized tender point sites. |
| Secondary | Fibromyalgia Disease Severity Assessed by Revised Fibromyalgia Impact Questionnaire (FIQR) | Baseline (before the first exercise session), after the first exercise session (Day 1), and at the end of 12 weeks. | Disease severity will be evaluated using the Revised Fibromyalgia Impact Questionnaire (FIQR). |
| Secondary | Health-Related Quality of Life Measured by SF-36 | Baseline (before the first exercise session), after the first exercise session (Day 1), and at the end of 12 weeks. | Health-related quality of life will be assessed using the Short Form-36 Health Survey (SF-36). |
| Secondary | Cognitive Function Assessed by Stroop Test | Baseline (before the first exercise session) and at the end of 12 weeks. | Cognitive function including attention, processing speed, executive function, and cognitive flexibility will be evaluated using the Stroop Test. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07851896
GET https://conductscience.org/api/trials/v1/NCT07851896/registered